Similar data were reported for pediatric patients with T-ALL treated according to the ALL-BFM protocol [9, 10], a comparable regimen to that of NHL-BFM group administered to T-LBL patients, suggesting that NOTCH1 mutations might serve as a positive prognostic marker in the context of BFM-type treatment. The gene discussed is NOTCH1; the disease is acute lymphoblastic leukemia.